Press releases

Month Year

Email alerts

Mar 10, 2013

New Data Reinforce Significant Blood Pressure Reduction Sustained to Two Years Using the Symplicity(TM) Renal Denervation System

24-Month Clinical Update from Symplicity HTN-2 Presented Today at the 62nd Annual Scientific Session of the American College of Cardiology

MINNEAPOLIS and SAN FRANCISCO - March 10, 2013 - Medtronic, Inc. (NYSE: MDT) today announced 24-month data from Symplicity HTN-2, the first randomized clinical trial investigating renal...
Mar 8, 2013

Medtronic CFO Gary Ellis to Speak at Barclays Global Healthcare Conference

MINNEAPOLIS - Mar 8, 2013 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference on...
Mar 7, 2013

Medtronic Submits IDE to FDA for U.S. Randomized Clinical Trial for Uncontrolled Hypertension Patients with Systolic Blood Pressure Between 140-160 mm Hg

IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic's Rigorous Global Clinical Trial Program for Hypertension Treatment

MINNEAPOLIS - March 7, 2013 - Medtronic, Inc. (NYSE: MDT), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA)...
Mar 6, 2013

Symplicity(TM) Renal Denervation System One of First Devices Accepted to Participate in Concurrent Review for Joint FDA Premarket Approval and Medicare National Coverage Determination

FDA-CMS Parallel Review Program Designed to Enable Efficient and Earlier Patient Access to Innovative Medical Advancements

MINNEAPOLIS - March 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA)and the Centers for Medicare & Medicaid Services (CMS) have accepted the...
Mar 5, 2013

Medtronic Announces CE Mark and European Launch of Attain Performa® Portfolio of Quadripolar Leads

New Lead Portfolio Provides Options for Physicians to Deliver CRT Optimally and Efficiently

MINNEAPOLIS - March 5, 2013 - Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark and will begin the European launch of the Attain Performa® portfolio of...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa